CMEOF (Creo Medical Group) Net Income (Continuing Operations): $-23.12 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMEOF Creo Medical Group PLC CMEOF
29 GF Score
Price $0.23
GF Value $0.40
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Net Income (Continuing Operations)?

Creo Medical Group CMEOF 29 Net Income (Continuing Operations) is $-23.12 Mil as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 29/100 and a GF Value™ of $0.40 (Possible Value Trap). The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Creo Medical Group's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was $-46.05 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was $-23.12 Mil.

Creo Medical Group  (OTCPK:CMEOF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Creo Medical Group Net Income (Continuing Operations) Related Terms

Creo Medical Group Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group Net Income (Continuing Operations) Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.71 -32.77 -30.00 -35.15 -23.43

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.32 -17.18 -18.08 22.93 -46.05
CMEOF
29GF Score
Creo Medical Group PLC CMEOF
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creo Medical Group Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-23.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-23.12 Mil mean?
Creo Medical Group (CMEOF) has a Net Income (Continuing Operations) of $-23.12 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Creo Medical Group and its competitors.
Is Creo Medical Group's Net Income (Continuing Operations) too high?
Creo Medical Group's current Net Income (Continuing Operations) is $-23.12 Mil. Overall, Creo Medical Group has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Net Income (Continuing Operations) compare to ABT and SYK?
Creo Medical Group's Net Income (Continuing Operations) of $-23.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current Net Income (Continuing Operations) is $-23.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (CMEOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.40, compared to a current price of $0.23 — trading 43.6% below its estimated fair value. The current Net Income (Continuing Operations) is $-23.12 Mil. Creo Medical Group's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Net Income (Continuing Operations) is $-23.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.23 is trading 43.6% below its estimated GF Value™ of $0.40. GuruFocus considers Creo Medical Group to be Possible Value Trap.

Key valuation signals for CMEOF:

  • Net Income (Continuing Operations): $-23.12 Mil
  • GF Value™: $0.40 vs. price of $0.23 (43.6% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
29GF Score

Get the complete analysis for CMEOF

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.40
GF Value